Poor
Needs Revision
Patient Risk:
Moderate
Summary
Multiple extracted claims are not supported by the provided label text (e.g., broad heart-disease risk reduction, energy-related effects, patent/generic/pricing statements, diabetes risk, and adverse effects from stopping). The audit also lacks verification of FDA-critical label sections such as contraindications and boxed warnings, creating major alignment gaps.
Category Scores
Accurate Statements
Lipitor (atorvastatin) works by inhibiting the production of cholesterol in the liver.
12.1 Mechanism of Action (HMG-CoA reductase inhibition and cholesterol synthesis in the liver)
Lipitor lowers low-density lipoprotein (LDL) cholesterol levels in the blood.
12.1 Mechanism of Action (reduces LDL-C; describes LDL as formed from VLDL and catabolized via LDL receptors)
Unsupported Statements
Lipitor (atorvastatin) is used to reduce the risk of heart disease.
The provided label text (1 INDICATIONS AND USAGE) discusses risk reduction in terms of individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia, but the excerpt does not explicitly support the phrasing 'reduce the risk of heart disease' as stated.
Lipitor has been widely prescribed since its approval in 1997.
No provided label section contains approval year or prescribing frequency information.
Some research suggests that Lipitor may have a positive impact on energy levels.
No provided label section mentions energy levels or increased energy as an effect.
Statins including Lipitor increase the expression of genes involved in energy metabolism.
No provided label section includes gene-expression findings.
Statins including Lipitor increase the expression of genes involved in the citric acid cycle.
No provided label section includes gene-expression findings.
Statins including Lipitor increase the expression of genes involved in oxidative phosphorylation.
No provided label section includes gene-expression findings.
Some people who take Lipitor have reported experiencing increased energy as a side effect of the medication.
No provided label section mentions increased energy as an adverse reaction.
A study in the Journal of Clinical Lipidology found that patients taking Lipitor had improved exercise tolerance compared to those taking a placebo.
14 CLINICAL STUDIES is placeholder text only; no provided label evidence supports this study.
A study in the Journal of Clinical Lipidology found that patients taking Lipitor had increased energy levels compared to those taking a placebo.
14 CLINICAL STUDIES is placeholder text only; no provided label evidence supports this study.
Common side effects of Lipitor include an increased risk of diabetes.
No provided label section mentions diabetes risk.
Lipitor's patent expired in 2011.
No provided label section contains patent or exclusivity information.
Generic versions of Lipitor entered the market after the patent expired in 2011.
No provided label section contains patent/generic market information.
DrugPatentWatch.com reports that reduced prices and increased competition occurred after Lipitor's patent expired.
No provided label section contains pricing/competition information or references to DrugPatentWatch.com.
Stopping Lipitor without consulting a healthcare provider can lead to adverse effects.
The provided patient counseling excerpt emphasizes adherence, but does not explicitly state that stopping without consulting causes adverse effects.
Contradictions
Important Omissions
Contraindications content was not evaluated because the label excerpt for 4 CONTRAINDICATIONS is placeholder/empty.
Importance:
High
Boxed warning / boxed-warning placement was not evaluated because 5 WARNINGS AND PRECAUTIONS excerpt is placeholder/empty.
Importance:
High
Dosage and administration safety (e.g., specific dosing instructions, limits, monitoring) was not evaluated because 2 DOSAGE AND ADMINISTRATION is not provided.
Importance:
High
Use in specific populations (e.g., pregnancy, pediatrics) was not evaluated because 8 USE IN SPECIFIC POPULATIONS is placeholder/empty.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related claims are unsupported or overbroad relative to the provided label text (e.g., diabetes risk; adverse effects from stopping without consulting). Additionally, critical label sections (contraindications, boxed warnings, dosing safety, and specific-population guidance) were not verifiably audited due to missing label content.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Multiple claims are not supported by the provided label excerpts, including safety assertions and a broad indication/risk-reduction statement not matched to the label wording. FDA-critical sections (contraindications, boxed warnings, dosing safety, pregnancy/pediatrics) are not evaluable from provided text.
Suggested Improvement
Restrict claims to wording supported by provided label sections (especially exact indication language in 1 INDICATIONS AND USAGE and mechanism in 12.1). Remove unsupported claims (energy/gene-expression/exercise tolerance, diabetes risk, patent/generic/pricing, and stopping-related adverse effects) unless the full label text supports them. Provide and evaluate the missing label sections (2, 4, 5, 8) before making dosing/safety-related statements.